Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2017 3 525 M
EBIT 2017 1 134 M
Net income 2017 910 M
Debt 2017 1 687 M
Yield 2017 0,44%
Sales 2018 4 373 M
EBIT 2018 1 428 M
Net income 2018 1 177 M
Debt 2018 1 112 M
Yield 2018 0,49%
P/E ratio 2017 25,88
P/E ratio 2018 20,08
EV / Sales2017 7,16x
EV / Sales2018 5,64x
Capitalization 23 562 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
06/09 3SBIO : Voluntary announcement - epiao received marketing authorization to launc..
06/09 3SBIO : Voluntary announcement - tpiao being granted an approval for drug clinic..
05/25 3SBIO : VOLUNTARY ANNOUNCEMENT - Right of Distribution and Promotion of New Prod..
05/25 3SBIO : Monthly Return of Equity Issuer on Movements in Securities for the month..
05/17 3SBIO : granted distribution right of insulin product in China
02/24 3SBIO : says 3 products listed in 2017 National Drug List
2016 3SBIO : granted exclusive license of diabetes drugs
2016 3SBIO : AstraZeneca Ink Licensing Agreement
2016 3SBIO : gets nod for colorectal cancer drug clinical trial
2016DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
More news
Sector news : Biopharmaceuticals
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Biopharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 10,6  CNY
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jing Lou Chairman, President & Chief Executive Officer
Wei hong Xiao Chief Operating Officer
Bo Tan Chief Financial Officer & Executive Director
Zhenping Zhu Chief Scientific Officer, President-R&D
Dong Mei Su Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
3SBIO INC. (ADR)3 448
BIOGEN7.26%59 460
CSL LIMITED42.74%49 053
ALEXION PHARMACEUTICAL..3.04%28 310
GRIFOLS SA39.01%18 339
BIOMARIN PHARMACEUTICA..14.68%16 577
More Results